23andMe, working in collaboration with the Milken Institute and Lundbeck, today announced that they have commenced enrollment for a first-of-its kind genetic study designed to gain understanding of the underlying biology of major depressive and bipolar disorders. This study will combine cognitive assessments with genetic data and survey responses to assess how genes influence brain processes – such as attention, decision-making and visual perception – in individuals who live with these serious mental health conditions.
“We know genetics play a role in the development of depression and bipolar, however there is a long pathway from our genes to the manifestation of complex diseases like these,” said Emily Drabant Conley, PhD., Vice President of Business Development at 23andMe. “We need to look at these conditions in a more comprehensive way to advance our understanding. By studying cognitive function alongside genetics and other environmental variables on a massive scale, we hope to take a significant step forward in the study of depression and bipolar.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8150951-23andme-genetic-study-depression-bipolar-disorders/
An international team of researchers led by Gerard D. Schellenberg, PhD, a member of the CurePSP Genetics Consortium and professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania, has identified three new genes that can increase the risk of people developing Progressive Supranuclear Palsy (PSP).
PSP is a rare neurodegenerative brain disease, similar to Parkinson’s disease, which causes severe disability by destroying parts of cells that allow the brain to function normally. While PSP has underlying biological similarities to Alzheimer’s disease, a disease which primarily affects memory, PSP impacts a person’s physical movement and bodily functions. PSP leads to progressive decline in patients — there is no known cause or cure.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/psp/49958/
In collaboration with the National Institutes of Health (NIH), Banner Alzheimer’s Institute (BAI), University of Antioquia in Colombia and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announce the first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history. This groundbreaking study—the first to investigate whether an anti-amyloid treatment can stave off the disease—will span two countries and help launch a new era of prevention research in the urgent fight against Alzheimer’s.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56128-banner-alzheimer-s-institute-genentech-nih-prevention-trial-genetics
ature Reviews Genetics (NRG) and Arkitek today jointly announce the launch of a new version of the popular RNA interference animation originally launched on NRG’s site in 2004. Arkitek and Nature Reviews Genetics decided to update the RNAi animation to showcase the new information learned about the functions of small RNAs.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53855-nature-reviews-genetics-and-arkitek-announce-rna-interference-animation
Phoenix Children’s Hospital announced the creation of the Ronald A. Matricaria Institute of Molecular Medicine today, with the goal to unlock genetic codes and develop drug therapies in real time to improve the outcome for thousands of young patients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59399-phoenix-children-s-hospital-visionary-institute-of-molecular-medicine
As early as age 25, women can begin to show the first signs of age in the form of fine lines and wrinkles, crow’s feet, and loss of skin clarity and radiance. These changes are due in part to the cumulative effects of free radical damage, including exposure to sun and pollution, stress, certain lifestyle habits, genetics, and wear and tear of life.
ARTISTRY, the premium beauty brand of Amway, introduces its ARTISTRY YOUTH XTEND Collection. This comprehensive skincare collection addresses the first visible signs of aging to help revitalize the future of skin, repair, and protect skin to keep it looking younger, longer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61024-amway-artistry-brand-introduces-artistry-youth-xtend-collection
Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman’s risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of “interrupting” DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism
Amway North America today launched BODYKEY by NUTRILITE™, a weight management program rooted in genetics that reveals exactly how a person should eat to most effectively manage their weight.
BODYKEY by NUTRILITE weight loss plans are based on an individual’s unique genetic makeup. The new program combines eating well, fitness, nutrition and a take-at-home genetic test to determine if a person’s body responds better to cutting carbs, reducing fat or a balanced diet.
To view Multimedia News Release, go to http://www.multivu.com/players/English/60257-amway-bodykey/
It’s the eve of the twenty-second century: a world where the dearly departed send postcards back from Heaven and evangelicals make scientific breakthroughs by speaking in tongues; where genetically engineered vampires solve problems intractable to baseline humans and soldiers come with zombie switches that shut off self-awareness during combat. And it’s all under surveillance by an alien presence that refuses to show itself.
Daniel Bruks is trapped on a ship bound for the center of the solar system. To his left is a grief-stricken soldier, obsessed by whispered messages from a dead son. To his right is a pilot who hasn’t yet found the man she’s sworn to kill on sight. A vampire and its entourage of zombie bodyguards lurk in the shadows behind. And dead ahead, a handful of rapture-stricken monks takes them all to a meeting with something they will only call “The Angels of the Asteroids.”
Their pilgrimage brings Dan Bruks, the fossil man, face-to-face with the biggest evolutionary breakpoint since the origin of thought itself. Find out more at http://us.macmillan.com/author/peterwatts. Scifi
www.Pyranosis.com - Recently-discovered information from the Sumerian records by Dr. Scott McQuate exposes secrets that have been hidden for thousands of years within the Cuneiform and even the Bible. This never-before-seen research reveals forbidden knowledge that connects human genetics with Israel, Eden and the Great Pyramid of Egypt. It is some of the most fascinating information you will ever see and challenges all previous religious dogma and scientific curriculum. Go now and discover what the world has never known. www.Pyranosis.com - Also be sure to watch his lecture at http://youtu.be/GEe7jIkn0Js
High-powered research teams supported by the Crohn's & Colitis Foundation of America (CCFA) are gearing up for an ambitious new goal: developing individualized treatment approaches for patients with Crohn's disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD), through their Genetics and Microbiome Research Initiatives.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65964-ccfa-genetic-microbiome-discoveries-ibd-crohn-s-disease-ulcerative-colitis
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
